Joanna L. Spencer-Segal
Neuroscience · University of Michigan
Publications
70
Citations
3,274
Est. group size
~10
Recurring co-author estimate
Active years
22
Publishing since 2005
Typically publishes in teams of ~12 · 33% small-team papers (≤3 authors) · across 13 venues
- Current controversies in acromegaly care
The Journal of Clinical Endocrinology & Metabolism · 2026
- Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study
Journal of the Endocrine Society · 2025
- Physiological Effects of Estradiol in the Mouse Hippocampal Formation
Digital Commons - RU (Rockefeller University) · 2025
- Wake Up and Smell—the Cortisol?
The Journal of Clinical Endocrinology & Metabolism · 2025
- Results from the core phase of the open-label, phase 3 ACROINNOVA 2 trial: CAM2029, a subcutaneous octreotide depot, achieves sustained, long-term biochemical control in acromegaly
Endocrine Abstracts · 2025
- SUN-097 CAM2029 Octreotide Subcutaneous Depot Maintains Control of IGF-I and Symptoms of Acromegaly Across the 4-Week Dosing Interval and During Intervals Greater Than 28 Days: Data from the ACROINNOVA 1 Trial
Journal of the Endocrine Society · 2025
- 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia
Critical Care Medicine · 2024
- Corticosteroids in Sepsis and Septic Shock: A Systematic Review, Pairwise, and Dose-Response Meta-Analysis
Critical Care Explorations · 2024
- Executive Summary: Guidelines on Use of Corticosteroids in Critically Ill Patients With Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia Focused Update 2024
Critical Care Medicine · 2024
- Adverse Effects Related to Corticosteroid Use in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis
Critical Care Explorations · 2024
- Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1
The Journal of Clinical Endocrinology & Metabolism · 2024
- 7373 CAM2029, Octreotide Subcutaneous Depot, Provides Sustained Biochemical Control of Acromegaly: Interim Results From a Phase 3 Study (ACROINNOVA 2)
Journal of the Endocrine Society · 2024
- 7376 Efficacy and Safety of CAM2029 in Patients With Controlled or Inadequately Controlled Acromegaly on Standard-of-Care Treatment: Interim Data for the “New to CAM2029” Patient Subgroup in a Phase 3 Study (ACROINNOVA 2)
Journal of the Endocrine Society · 2024
- #1705024 A Randomized Phase 3 Trial to Assess Efficacy and Safety of a Novel Formulation of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
Endocrine Practice · 2024
- 7377 CAM2029, Octreotide Subcutaneous Depot, Improves Patient-Reported Outcomes From Standard-of-Care Baseline in Patients With Acromegaly: Interim Results From a Phase 3 Study (ACROINNOVA 2)
Journal of the Endocrine Society · 2024
- Journal of the Endocrine Society×17
- The Journal of Clinical Endocrinology & Metabolism×4
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Nature Reviews Endocrinology×2
- Critical Care Medicine×2
- Hedieh Briggs
Neuroscience · University of Michigan
- William B. Malarkey
Neuroscience · The Ohio State University
- Colin Johnston
Neuroscience · University of Michigan
- Delia M. Vázquez
Neuroscience · University of Michigan
- Andrew R. Burke
Neuroscience · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile